Innovent Biologics (HK:1801)
:1801
Want to see HK:1801 full AI Analyst Report?
1801 Stock Chart & Stats
HK$91.50
-HK$0.85(-2.50%)
At close: 4:00 PM EST
HK$91.50
-HK$0.85(-2.50%)
Day’s Range― - ―
52-Week RangeHK$68.55 - HK$109.10
Previous CloseN/A
Volume9.75M
Average Volume (3M)16.11M
Market Cap
HK$137.06B
Enterprise ValueHK$110.35B
Total Cash (Recent Filing)HK$18.24B
Total Debt (Recent Filing)HK$2.82B
Price to Earnings (P/E)139.6
Beta0.62
Next Earnings
Aug 26, 2026EPS Estimate
1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.50
Shares Outstanding1,738,237,200
10 Day Avg. Volume15,175,046
30 Day Avg. Volume16,110,837
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)6.12
Price to Sales (P/S)9.09
P/FCF Ratio12.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$119.78Price Target Upside30.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)1.38
Revenue Forecast (FY)HK$18.43B
Bulls Say, Bears Say
Bulls Say
Strengthened Cash GenerationA large swing to positive operating cash flow and FCF in 2025 materially improves the company’s ability to self-fund R&D, scale commercialization, and service capital needs without relying on equity raises. If sustained, strong cash conversion supports durable reinvestment and lowers financing risk over the next 2–6 months and beyond.
Conservative Leverage And Stronger Equity BaseSignificantly lower leverage and a larger equity base provide financial flexibility to absorb setbacks and invest in pipeline execution. A conservative balance sheet improves resilience to reimbursement timing, clinical delays, or cyclical revenue swings and supports long-term strategic options like partnerships or manufacturing capacity expansion.
High Gross Margin And Revenue InflectionVery high gross margins indicate scalable biologics manufacturing and pricing power for marketed drugs, while the revenue inflection shows accelerating commercial traction. Together these structural traits support margin sustainability and capacity to fund further clinical and market expansion if top-line growth persists.
Bears Say
Prior Operating Losses And Uneven Track RecordThe company’s profitability only turned positive in 2025 after multiple years of losses and inconsistent cash flow. This uneven historical performance raises the risk that the 2025 improvement may be partly cyclical or timing-related, and that sustainable operating margins are not yet proven across economic cycles.
Modest Net Margin And Low ReturnsDespite strong gross margins, net profitability remains modest and return metrics are low, limiting the firm’s buffer against cost inflation, price pressure, or competitive price erosion. Low net margins mean incremental revenue must be large to drive material earnings and ROE improvement, increasing execution demands.
Concentration In China CommercializationHeavy reliance on Chinese hospital channels and reimbursement frameworks concentrates regulatory, pricing, and demand risk. Structural shifts in national reimbursement policy, hospital procurement, or competitive local entrants could materially affect revenue durability given limited geographic diversification in the business model.
Innovent Biologics News
1801 FAQ
What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was HK$68.55 and its highest was HK$109.10 in the past 12 months.
What is Innovent Biologics’s market cap?
Innovent Biologics’s market cap is HK$137.06B.
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s upcoming earnings report date is Aug 26, 2026 which is in 83 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Mar 26, 2026. The company reported -HK$0.012 earnings per share for the quarter, missing the consensus estimate of HK$0.139 by -HK$0.151.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is 1.26.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,738,237,200 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of -HK$0.012 in its last earnings report, missing expectations of HK$0.139. Following the earnings report the stock price went down -3.816%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in HK:1801
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innovent Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$119.78 (30.90% Upside)
HK$119.78 (30.90% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
101.65%
12-Months-Change
Fundamentals
Return on Equity
4.82%
Trailing 12-Months
Asset Growth
80.58%
Trailing 12-Months
Company Description
Innovent Biologics
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
1801 Stock 12 Month Forecast
Average Price Target
HK$119.78
▲(30.90% Upside)
Technical Analysis
3SBio
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---